Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:4937

Official publication of the Indian Society of Nephrology
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (420 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

   Article Figures

 Article Access Statistics
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal


  Table of Contents  
Year : 2013  |  Volume : 23  |  Issue : 5  |  Page : 392

Extended spectrum beta lactamase peritonitis: Our experience

Department of Nephrology and Dialysis, Civic and Di Cristina Hospital, Palermo, Italy

Date of Web Publication8-Aug-2013

Correspondence Address:
G Li Cavoli
43 Via Francesco Cilea, 90144 Palermo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-4065.116334

Rights and Permissions

How to cite this article:
Cavoli G L, Schillaci O, Tralongo A, Tortorici C, Bono L, Ferrantelli A, Rotolo U. Extended spectrum beta lactamase peritonitis: Our experience. Indian J Nephrol 2013;23:392

How to cite this URL:
Cavoli G L, Schillaci O, Tralongo A, Tortorici C, Bono L, Ferrantelli A, Rotolo U. Extended spectrum beta lactamase peritonitis: Our experience. Indian J Nephrol [serial online] 2013 [cited 2022 Dec 5];23:392. Available from:


We read with interest the article of Dr. Sinha and Coll [1] on extended spectrum beta-lactamase (ESBL) peritonitis in patient on chronic peritoneal dialysis (PD). The guidelines of International Society for PD [2] state that the selection of empiric antibiotics must cover all serious pathogens that are likely to be present, through a first-generation cephalosporin, such as cefazolin or cephalothin, with a second drug for broader Gram-negative coverage (including coverage for Pseudomonas) such as aminoglycoside, ceftazidime, cefepime, or carbapenem.

The guidelines of Italian Society of Nephrology state that intra-peritoneal (IP) administration of antibiotic agents is the most effective treatment of PD peritonitis; intermittent administration may be preferred to continuous administration of antibiotic agents in PD peritonitis. [3] We routinely, apply these guidelines in our clinical practice. We would like to report our similar experience: A 65-year-old Caucasian patient, suffering from autosomal dominant polycystic kidney disease, on chronic PD, was admitted to hospital for signs and symptoms of peritonitis (fever, abdominal pain, cloudy PD fluid effluent, a cell count of 9950/ml). He was started on IP cefazolin and tobramicine and IV ciprofloxacin, but in the next 72 h he worsened vomiting and abdominal pain. Abdominal CT scan [Figure 1] showed the presence in the bowels of significant fluid with intense gaseous component. The PD fluid culture was confirmed to be ESBL secreting Pseudomonas aeruginosa. Due to the severe clinical status, not having yet of susceptibility, we changed the empiric therapy starting intravenous meropenem 500 mg every 8 h a day. We observed a dramatic clinical improvement in the next 24 hours with disappearance of abdominal pain and vomiting and recovery of feeding. Having later known the result of the susceptibility pattern, positive for meropenem (minimum inhibitory concentration 0.25), we began IP therapy with this drug (500 mg/2 L). The antibiotic was continued for 2 weeks and a repeat PD fluid analysis showed a normal cell count and sterile culture.
Figure 1: Abdomen CT scan: Enlarged polycystic kidneys; presence in the bowel of significant fluid with intense gaseous component

Click here to view

Furthermore, in Italy, the menace of ESBL peritonitis is becoming increasingly common. We agree with the authors on the need for studies on the efficacy of meropenem in ESBL peritonitis and the best route of administration (IP or parenteral), as well as the need for a revision of the International Society for PD recommendations, incorporating suggestions for ESBL peritonitis.

  References Top

1.Sinha R, Bhakta A. Extended spectrum beta lactamase peritonitis: Time for innovation? Indian J Nephrol 2012;22:374-6.  Back to cited text no. 1
  Medknow Journal  
2.Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010;30:393-423.  Back to cited text no. 2
3.La Milia V, Virga G, D'Amico M, Russo R, Corciulo R, Amici A, et al. Treating peritonitis in peritoneal dialysis: Guideline from the Italian Society of Nephrology. G Ital Nefrol 2007;24:149-64.  Back to cited text no. 3


  [Figure 1]


Print this article  Email this article


Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07